Document is current

Article History

Accepted: 12 March 2025

First Online: 28 March 2025

Declarations

:

: A.G.O.L. is the former President of the Pacific Dermatology Association and serves as an associate editor for Dermatology (Karger) and editorial board member of the American Journal of Clinical Dermatology. A.G.O.L. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Additionally, he is a consultant for Genentec, Guidepoint, InflaRx, Corvus pharmaceuticals, Castle Biosciences, Clarivate, TFS HealthScience, Otsuka, and Leo Pharma. He is an advisor to Bristol-Meyers Squibb, Boehringer Ingelheim, Janssen, and Sanofi. Dr. Ortega has received research grants from Lilly, Janssen, Incyte and Pfizer. He is supported by National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01 AR083110. A.H.B. served on the advisory board for Boehringer Ingelheim and Blueprint Medicines for unrelated disease states. Authors S.L.B. and C.T. have no conflicts to disclose.

: No funding was received for this project.

: No data were generated in the creation of this manuscript.

: Patients signed informed consent regarding publishing their data and photographs.

: Not applicable.

: Not applicable.

: Not applicable.

: Original text—S.L.B. Critical revisions—A.G.O.L., C.T., and A.H.B. All authors read and approved the final version.